Clinical Trial Update: Safety, Tolerability, and Immunogenicity of the Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO), VRC-EBOADC069-00-VP, in Healthy Adults [Phase 1]

View source ↗

Summary

Phase 1 study evaluating safety, tolerability, and immunogenicity of the Ebola vaccine cAd3-EBO in healthy adults.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ebola Virus Disease

Drugs mentioned

• Ebola chimpanzee adenovirus vector vaccine (cAd3-EBO)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Healthy Adult Immune Responses to Vaccine | Phase 1 | Status: COMPLETED